Navigation Links
Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib,Combination Studies

p>

"The results of these combination studies demonstrated that seliciclib could be safely combined with gemcitabine/cisplatin or docetaxel with evidence of anti-tumor activity. However the contribution of seliciclib to the anti-tumor activity of the combinations could not be adequately evaluated in a non-randomized study. To assess the anti-tumor activity of seliciclib as a single agent, we are currently conducting a double-blinded, randomized, Phase II study of single agent seliciclib versus best supportive care in patients with advanced NSCLC who have had at least two prior systemic therapies (the APPRAISE study). In addition, we are currently planning a randomized Phase II study of single agent seliciclib in patients with previously treated nasopharyngeal cancer (NPC)", commented Dr. Judy Chiao, Vice President of Clinical Development and Regulatory Affairs of Cyclacel.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Two Cyclacel drugs are in Phase II trials: sapacitabine (CYC682), an orally-available, cell cycle modulating nucleoside analog, for the treatment of cutaneous T-cell lymphoma (CTCL) and seliciclib (CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, for the treatment of lung cancer. Sapacitabine is also in Phase I trials in patients with hematologic malignancies. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is at the IND stage. Several additional programs are at an earlier stage.

Please visit http://www.cyclacel.com/cyc/investors/news/pressreleases for additional information.

Note: The Cyclacel logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actua
'"/>




Page: 1 2 3

Related medicine technology :

1. Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting
2. Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Post Your Comments:
(Date:11/23/2009)...Calif.,Nov.23/PRNewswire-FirstCall/--Neurobiologic...todaythatitsboardofdirectorshasdeclaredanextraordi...bepaidonDecember9,2009tostockholdersofrecordasofNo...ndfollowsstockholderapprovalofthedissolutionofNTIp...ndanearlierextraordinarydividendof$0.75persharetha...
(Date:11/21/2009)...N, Nov. 21 An urgent need for new ...n the developing world has prompted a growing numb...on-profit product development partnerships (PDPs),...s noted today in a symposium at the 58th annual me... and Hygiene (ASTMH), these collaborations are ope...
(Date:11/20/2009)...la., Nov. 20 Unilens Vis...xchange: UVI), which develops, licenses, manufactu...ses, today reported its operating results for the ..., Net sales excluding royalty income, were $1,6... $1,761,526 reported in the previous year first qu...
Breaking Medicine Technology:Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share 2ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 2ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 3Unilens Vision Reports Record First Quarter Earnings and Royalty Income 2Unilens Vision Reports Record First Quarter Earnings and Royalty Income 3Unilens Vision Reports Record First Quarter Earnings and Royalty Income 4Anesthesia Society Selects Sanford Brown Institute Instructor as Educator of the Year 61187 1Anesthesia Society Selects Sanford Brown Institute Instructor as Educator of the Year 61187 2Anesthesia Society Selects Sanford Brown Institute Instructor as Educator of the Year 61187 3Surgery Not Always Best for Narrowed Kidney Arteries 61185 1Surgery Not Always Best for Narrowed Kidney Arteries 61185 2Surgery Not Always Best for Narrowed Kidney Arteries 61185 3Tamiflu Resistant Swine Flu Found in Canadian Father 61183 1Tamiflu Resistant Swine Flu Found in Canadian Father 61183 2Tamiflu Resistant Swine Flu Found in Canadian Father 61183 3
... /PRNewswire-FirstCall/ --,Medivation, Inc. today ...30 a.m. Eastern time on Monday, June 11, to discus...ouble-blind,placebo-controlled Phase 2 clinical t...n Alzheimer,s disease. , Rachelle Doody, M.D., Ph....the 12-month results for the first time at a,scien...
... 7, 2007 - Clinical results from a,Phase II study ...che Society (AHS) annual meeting showed that MK-09...d peptide (CGRP),receptor antagonist, significantl...sing compared to placebo, and the relief was,susta...tolerated in,the study. Responses specific to othe...
Other Medicine Technology:Medivation to Host Conference Call to Discuss Top-Line 12-Month,Results From Dimebon Alzheimer's Disease Study 2Medivation to Host Conference Call to Discuss Top-Line 12-Month,Results From Dimebon Alzheimer's Disease Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5
(Date:11/23/2009)...RIE,Minn.,Nov.23/PRNewswire/--XiotechCorporationto...entedanEmprise(TM)7000storagesystem,poweredbyIntel...tscurrentdatastorageneeds,enablefuturegrowthanddel...sacrossitsdatacenter. ,, MasonGeneral,locatedin...tworks magazine,s"MostWired-Rural"hospitalsin2008a...
(Date:11/23/2009)...NS,Nov.23/PRNewswire/--Thanksgivingweekendmarksthe...radition,theClassicrepresentsthesportsmanshipandpr...yofNewOrleansandthoseinattendance. ,, Forthecre...anceforsomedowntimebeforetheyworktotestandlaunchab...ofconstruction,PettyOfficerClaudeBovellandtheresto...
(Date:11/23/2009)... suggest that adding flaxseed oil to the diet coul...al women and women with diabetes, according to a r...l of Food Safety, Nutrition and Public Health . ,...h Center, in Cairo, Egypt, have studied the effect...seed oil in the diet might delay the onset of oste...
(Date:11/23/2009)...op plants genetically modified to produce bacteria...safe for people, have been planted on more than 20...ese Bt crops, named after the bacterium Bacillus ...ome major pests, allowing farmers to save money an...cide sprays. , However, since insects can evolve...
(Date:11/23/2009)...hemo regimen may improve patient outcomes, researc...y News) -- A new combination drug therapy shows pr...ract cancers, researchers say. , The study from...in Boston found that survival and tumor response i...angiogenesis inhibitor that has helped slow the gr...
Breaking Medicine News(10 mins):Health News:ISE Technology by Xiotech Helps Hospital Achieve Data Center Efficiency, Savings 2Health News:Nothing Is Like Being There 2Health News:Flaxseed oil and osteoporosis 2Health News:Insect resistance to Bt crops can be predicted, monitored and managed 2Health News:Combo Treatment Beneficial in Biliary-Tract Cancer Study 2
...Total U.S. Market for Women,s Health Devices Worth...swire/ - According to two market research reports ...nternational medical device, dental and pharmaceut...erilization devices, which grew over 54% in 2008, ...
...Unique fashion accessory adds a fun, playful pop o... good; Stylish low-cost pendants support disabled ...CLARA, Calif., May 5 - Ground-breaking Art of Po...unced it has finalized a licensing agreement with ...
... Out of adversity comes op...icant words uttered more than 250 years ago ring t...day. , New York, NY (Vocu...ring true for the Gift of Life Bone Marrow Found...
... The Better Hearing Instit... for Better Hearing and Speech Month: Listening Up...aring health affects job security, performance, an...t unaddressed hearing loss does not pose a barrier...
... ZyDoc Medical Transcripti...as chosen ZyDoc,s award-winning web-based e-transc...ents. , Hauppauge, New Yo...in business since 1994, has chosen ZyDoc,s award-w...
... Renowned Dentist Robert L... Cosmetic Dentistry is one of the few Doctors in P...n for oral sedation dentistry. , ...ly that the practice has earned its certification ...
Other Medicine News:Health News:U.S. Market for Female Sterilization Devices to Grow 36% in 2009 2Health News:Playing with Fashion: New 'Phenominoes' Pendants Feature Blind Artists' Phenomenal Artwork on Real Dominoes 2Health News:Playing with Fashion: New 'Phenominoes' Pendants Feature Blind Artists' Phenomenal Artwork on Real Dominoes 3Health News:Playing with Fashion: New 'Phenominoes' Pendants Feature Blind Artists' Phenomenal Artwork on Real Dominoes 4Health News:Playing with Fashion: New 'Phenominoes' Pendants Feature Blind Artists' Phenomenal Artwork on Real Dominoes 5Health News:Bone Marrow Registry to Launch Groundbreaking Fundraising Technology to Overcome Madoff Crisis 2Health News:Listening Up in a Down Economy: Better Hearing Institute Launches Public Service Campaign for Better Hearing and Speech Month 2Health News:Listening Up in a Down Economy: Better Hearing Institute Launches Public Service Campaign for Better Hearing and Speech Month 3Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 2Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 3Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 4Health News:Raleigh Comprehensive and Cosmetic Dentistry Earns Certification For Sedation Dentistry 2Health News:Raleigh Comprehensive and Cosmetic Dentistry Earns Certification For Sedation Dentistry 3
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
Medicine Products: